RxDoctor Payments Data

Joseph McAllister, MD

Internal Medicine · Abington, PANPI 1023014545

Payments from drug & device makers

$8,302in general payments, 2019–2025

Across 347 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AstraZeneca$994
  • Novo Nordisk$923
  • GSK$761
  • Lilly USA, LLC$730
  • Amgen$567
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$8,279100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,302 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$273,009
Medicare patients
804
Services billed
2,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$88,218
JardianceEmpagliflozin90$84,261
OzempicSemaglutide49$55,417
XareltoRivaroxaban35$40,903
MounjaroTirzepatide18$18,238
Breo ElliptaFluticasone/Vilanterol15$11,718
LinzessLinaclotide15$10,897
Atorvastatin Calcium555$6,417
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$5,803
Simvastatin463$5,409
Levothyroxine Sodium447$5,178
SynthroidLevothyroxine Sodium82$4,984
SymbicortBudesonide/Formoterol Fumarate23$4,850
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,529
Rosuvastatin Calcium345$4,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,569$88,21895 claims
Boehringer IngelheimJardiance$64$84,26190 claims
Novo NordiskOzempic$923$55,41749 claims
Johnson & JohnsonXarelto$323$40,90335 claims
Lilly USA, LLCMounjaro$730$18,23818 claims
AbbVieLinzess, Synthroid$95$15,88197 claims
GSKBreo Ellipta$761$11,71815 claims
AstraZenecaSymbicort$994$4,85023 claims
Almatica Pharma LLCSertraline Hcl$92$1,881203 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →